目次

Table of Contents

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Lab-based analysis
2.2.1.3 Approach 3: Drug class-based analysis
2.2.1.4 Approach 4: Presentations of companies and primary interviews
2.2.1.5 Growth forecast
2.2.1.6 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ASSESSMENT
2.5 RESEARCH ASSUMPTIONS
2.6 STUDY LIMITATIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE,
BY DRUG CLASS AND COUNTRY (2023)
4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY
4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029
4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Importance of therapeutic drug monitoring in
organ transplant procedures
5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields
5.2.1.3 Increasing preference for precision medicine
5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring
5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
5.2.1.6 Increasing prevalence of epilepsy
5.2.1.7 Rising prevalence of cancer
5.2.2 RESTRAINTS
5.2.2.1 High capital investments
5.2.2.2 Reluctance of small hospitals to offer therapeutic
drug monitoring services
5.2.3 OPPORTUNITIES
5.2.3.1 Significant opportunities in BRICS countries
5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
5.2.3.3 Integration of AI and machine learning
5.2.4 CHALLENGES
5.2.4.1 Alternatives to conventional therapeutic drug monitoring
5.2.4.2 Operational challenges and inadequate infrastructure to restrict
TDM testing in low- and middle-income countries
5.2.4.3 Shortage of skilled professionals
5.3 PRICING ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 REGULATORY LANDSCAPE
5.7.1 NORTH AMERICA
5.7.1.1 US
5.7.1.2 Canada
5.7.2 EUROPE
5.7.3 ASIA PACIFIC
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.4 LATIN AMERICA
5.7.5 MIDDLE EAST
5.7.6 AFRICA
5.8 TRADE ANALYSIS
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGY
5.12.1.1 Enzyme-linked immunosorbent assay
5.12.2 COMPLEMENTARY TECHNOLOGY
5.12.2.1 Liquid chromatography-mass spectrometry
5.12.3 ADJACENT TECHNOLOGY
5.12.3.1 Electrophoresis
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 INTENSITY OF COMPETITIVE RIVALRY
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 THREAT OF SUBSTITUTES
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC
DRUG MONITORING MARKET

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
6.3 EQUIPMENT
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 High efficiency to drive adoption
6.3.2 CHROMATOGRAPHY & MS DETECTORS
6.3.2.1 Technological advancements to propel growth
6.3.3 CLINICAL CHEMISTRY ANALYZERS
6.3.3.1 Increasing incidence of chronic and complex diseases to
drive market

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
7.2.1.1 Accurate measurement of target-specific proteins to drive market
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.2.1 Rapid detection time and good specificity to support growth
7.2.3 FLUORESCENCE IMMUNOASSAYS
7.2.3.1 High operability and better sensitivity of FIAs to drive market
7.2.4 COLORIMETRIC IMMUNOASSAYS
7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
7.2.5 OTHER IMMUNOASSAYS
7.3 CHROMATOGRAPHY-MS
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.1.1 High accuracy to drive demand for LC-MS
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.2.1 Drawbacks of GC-MS to challenge market growth
7.4 OTHER TECHNOLOGIES

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
8.1 INTRODUCTION
8.2 ANTIEPILEPTIC DRUGS
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
8.3 ANTIARRHYTHMIC DRUGS
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
8.4 IMMUNOSUPPRESSANT DRUGS
8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION
PROCEDURES TO DRIVE MARKET
8.5 ANTIBIOTIC DRUGS
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
8.6 BRONCHODILATOR DRUGS
8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND
FOR BRONCHODILATOR DRUG MONITORING
8.7 PSYCHOACTIVE DRUGS
8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
8.8 OTHER DRUGS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 NEUROLOGICAL DISORDERS
9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO
PROPEL MARKET
9.3 CARDIOLOGY
9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
9.4 INFECTIOUS DISEASES
9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
9.5 ONCOLOGY
9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
9.6 OTHER THERAPEUTIC AREAS

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN
10.1 INTRODUCTION
10.2 BLOOD
10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
10.3 SALIVA
10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
10.4 OTHER SAMPLES

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITAL LABORATORIES
11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS
PERFORMED TO DRIVE MARKET
11.3 COMMERCIAL & PRIVATE LABORATORIES
11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
11.4 OTHER END USERS

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
12.2.2 US
12.2.2.1 Increasing awareness regarding precision medicine to propel market
12.2.3 CANADA
12.2.3.1 Availability of funding for research to offer growth opportunities
12.3 EUROPE
12.4 EUROPE: MACROECONOMIC OUTLOOK
12.4.1 GERMANY
12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
12.4.2 UK
12.4.2.1 Increasing cases of chronic diseases to drive market
12.4.3 FRANCE
12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
12.4.4 ITALY
12.4.4.1 Rising incidence of cancer to drive demand
12.4.5 SPAIN
12.4.5.1 Adoption of technologically advanced immunoassays to
boost market
12.4.6 REST OF EUROPE
12.5 ASIA PACIFIC
12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
12.6.1 JAPAN
12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
12.6.2 CHINA
12.6.2.1 Rising number of organ transplants to boost market
12.6.3 INDIA
12.6.3.1 Rising incidence of cancer to propel market
12.6.4 AUSTRALIA
12.6.4.1 High healthcare expenditure and favorable government
initiatives to propel market
12.6.5 REST OF ASIA PACIFIC
12.7 LATIN AMERICA
12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
12.8 MIDDLE EAST & AFRICA
12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
12.9 GCC COUNTRIES
12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 RIGHT TO WIN
13.3 STRATEGIES ADOPTED BY KEY PLAYERS
13.4 REVENUE ANALYSIS
13.5 MARKET SHARE ANALYSIS
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
13.6.1 STARS
13.6.2 EMERGING LEADERS
13.6.3 PERVASIVE PLAYERS
13.6.4 PARTICIPANTS
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.6.5.1 Company footprint
13.6.5.2 Region footprint
13.6.5.3 Product footprint
13.6.5.4 Technology footprint
13.6.5.5 End-user footprint
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
13.7.1 PROGRESSIVE COMPANIES
13.7.2 RESPONSIVE COMPANIES
13.7.3 DYNAMIC COMPANIES
13.7.4 STARTING BLOCKS
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.7.5.1 Detailed list of key startups/SMEs
13.8 COMPANY VALUATION & FINANCIAL METRICS
13.8.1 FINANCIAL METRICS
13.8.2 COMPANY VALUATION
13.9 PRODUCT/BRAND COMPARISON
13.10 COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES
13.10.2 DEALS
13.10.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 ABBOTT
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 MnM view
14.1.1.3.1 Key strengths
14.1.1.3.2 Strategic choices
14.1.1.3.3 Weaknesses and competitive threats
14.1.2 THERMO FISHER SCIENTIFIC INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches
14.1.2.3.2 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 F. HOFFMANN-LA ROCHE LTD.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 SIEMENS HEALTHINEERS AG
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 DANAHER CORPORATION
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 BIO-RAD LABORATORIES, INC.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches
14.1.6.3.2 Deals
14.1.7 BIOMÉRIEUX SA
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.8 BIOSYNEX SA
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches
14.1.8.3.2 Deals
14.1.9 GRIFOLS, S.A.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Deals
14.1.10 EXAGEN INC.
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Deals
14.1.11 ARK DIAGNOSTICS, INC.
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.12 R-BIOPHARM AG
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Product launches
14.1.13 RANDOX LABORATORIES LTD.
14.1.13.1 Business overview
14.1.13.2 Products offered
14.2 OTHER PLAYERS
14.2.1 APDIA GROUP
14.2.2 BBI SOLUTIONS
14.2.3 EAGLE BIOSCIENCES, INC.
14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
14.2.5 AALTO SCIENTIFIC, LTD.
14.2.6 IMMUNDIAGNOSTIK AG
14.2.7 UTAK
14.2.8 SEKISUI MEDICAL CO., LTD.
14.2.9 DIASYSTEM SCANDINAVIA AB
14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
14.2.12 BÜHLMANN LABORATORIES AG
14.2.13 SJK GLOBAL, LLC
14.2.14 EPITOPE DIAGNOSTICS, INC.
14.2.15 QED BIOSCIENCE INC.
14.2.16 BODITECH MED INC.
14.2.17 IMMUNODIAGNOSTIC SYSTEMS

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS